Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $31.4 million.

  • Immunome's Total Current Liabilities fell 20.45% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 20.45%. This contributed to the annual value of $54.3 million for FY2024, which is 148.78% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Total Current Liabilities is $31.4 million, which was up 37.45% from $22.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Total Current Liabilities peaked at $54.3 million during Q4 2024, and registered a low of $21.8 million during Q4 2023.
  • For the 3-year period, Immunome's Total Current Liabilities averaged around $31.4 million, with its median value being $30.8 million (2024).
  • In the last 5 years, Immunome's Total Current Liabilities skyrocketed by 148.78% in 2024 and then tumbled by 42.66% in 2025.
  • Quarterly analysis of 3 years shows Immunome's Total Current Liabilities stood at $21.8 million in 2023, then skyrocketed by 148.78% to $54.3 million in 2024, then dropped by 20.45% to $31.4 million in 2025.
  • Its Total Current Liabilities was $31.4 million in Q3 2025, compared to $22.9 million in Q2 2025 and $30.8 million in Q1 2025.